---
search:
  boost: 3
---

# Antiarrhythmics

This is a subcategory of Cardiovascular Agents.

## Decision Trees

- [Cardiovascular - Antiarrhythmics - Amiodarone 100, 400mg](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM1lMQjdHVFZOQVBYMjREQkdEUDYxSzRJMSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Cardiovascular Antiarrhythmics - Multaq](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMFhJVUhGNE9CWklFUEdDODVJUElRSEFSSCQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                        | Generic Name                                              | Quantity | Time (Days) |
| :------------------------------- | :-------------------------------------------------------- | :------: | :---------: |
| Amiodarone 200mg <sup>QL</sup>   | Amiodarone HCI Tab 200 MG                                 |   816    |     102     |
| Disopyramide <sup>QL</sup>       | Disopyramide Phosphate Cap (all strengths)                |   816    |     102     |
| Dofetilide                       |                                                           |          |             |
| Flecainide <sup>QL</sup>         | Flecainide Acetate Tab (all strengths excl 100 MG)        |   306    |     102     |
| Flecainide <sup>QL</sup>         | Flecainide Acetate Tab 100 MG                             |   612    |     102     |
| Mexiletine <sup>QL</sup>         | Mexiletine HCI Cap (all strengths excl 150 MG)            |   306    |     102     |
| Mexiletine <sup>QL</sup>         | Mexiletine HCI Cap 150 MG                                 |   408    |     102     |
| Norpace CR <sup>QL</sup>         | Disopyramide Phosphate ER Cap (all strengths excl 150 MG) |   612    |     102     |
| Norpace CR <sup>QL</sup>         | Disopyramide Phosphate ER Cap R 150 MG                    |   408    |     102     |
| Propafenone IR, ER <sup>QL</sup> |                                                           |          |             |
| Quinidine IR, ER <sup>QL</sup>   |                                                           |          |             |

### Non-Preferred

| Non-Preferred                            | Generic Name                                   |         Quantity          |        Time (Days)        |
| :--------------------------------------- | :--------------------------------------------- | :-----------------------: | :-----------------------: |
| Amiodarone 100mg and 400mg <sup>QL</sup> | Amiodarone HCI Tab (all strengths excl 200 MG) | Determined pursuant to PA | Determined pursuant to PA |
| Multaq                                   |                                                |                           |                           |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=16&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=21){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=12){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
